Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research (GLITTER 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03371108
Recruitment Status : Active, not recruiting
First Posted : December 13, 2017
Last Update Posted : January 18, 2020
Sponsor:
Information provided by (Responsible Party):
Gan and Lee Pharmaceuticals, USA

Brief Summary:

Primary Objective:

• To evaluate equivalence of Gan & Lee Insulin Glargine Injection and Lantus® in terms of immunogenicity

Secondary Objective:

Immunogenicity:

• To evaluate the percentage of subjects with negative anti-insulin antibodies (AIA) at baseline who develop confirmed positive AIA up to Week 26, the percentage of subjects with at least a 4-fold increase in titers compared to baseline value, mean change from baseline in AIA titers between treatment groups, the percentage of subjects with confirmed positive AIA who develop any anti-insulin neutralizing antibodies up to visit Week 26, and the percentage of subjects in each treatment group with confirmed positive AIA up to visit Week 26

Safety:

• To evaluate the safety of Gan & Lee Insulin Glargine Injection in comparison with that of Lantus®

Efficacy:

• To evaluate the efficacy of Gan & Lee Insulin Glargine Injection in comparison with that of Lantus®


Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Biological: Gan & Lee Insulin Glargine Injection Biological: Lantus® Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 550 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Subjects who meet the study eligibility criteria will be centrally randomized 1:1 in an open-label fashion to receive either Gan & Lee Insulin Glargine Injection or Lantus® for 26 weeks.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 3 STUDY TO COMPARE THE IMMUNOGENICITY, EFFICACY, AND SAFETY OF GAN & LEE PHARMACEUTICALS INSULIN GLARGINE INJECTION TO LANTUS® IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS
Actual Study Start Date : October 31, 2017
Estimated Primary Completion Date : February 28, 2020
Estimated Study Completion Date : February 28, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Gan & Lee Insulin Glargine Injection
Gan & Lee Insulin Glargine Injection solution for subcutaneous injection, 100 U/mL, in the integrated, disposable 3.0 mL prefilled Gan & Lee injector pen. Subjects randomized to the Gan & Lee Insulin Glargine Injection group will participate in the study for 26 weeks.
Biological: Gan & Lee Insulin Glargine Injection
Route of administration: subcutaneous injection

Active Comparator: Lantus®
Lantus® solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL prefilled insulin pen. Subjects randomized to the Lantus® group will participate for 26 weeks.
Biological: Lantus®
Route of administration: subcutaneous injection




Primary Outcome Measures :
  1. Immunogenicity [ Time Frame: Up to Week 26 ]
    The percentage of subjects in each treatment group who develop treatment-induced AIAs, defined as newly confirmed positive AIA development or important (at least a 4 fold) increase in titers, after baseline and up to visit Week 26.


Secondary Outcome Measures :
  1. The change in HbA1c from baseline at visit Week 26 to be measured and reported [ Time Frame: Up to Week 26 ]
    The change in HbA1c from baseline at visit Week 26.

  2. Immunogenicity - Percentage of subjects in each treatment group with negative AIA at baseline who develop confirmed positive AIA after baseline [ Time Frame: Up to Week 26 ]
    The percentage of subjects in each treatment group with negative AIA at baseline who develop confirmed positive AIA after baseline and up to visit Week 26.

  3. Immunogenicity - Percentage of subjects in each treatment group with confirmed positive AIA at baseline and at least a 4-fold increase in titers after baseline [ Time Frame: Up to Week 26 ]
    The percentage of subjects in each treatment group with confirmed positive AIA at baseline and at least a 4-fold increase in titers after baseline and up to visit Week 26.

  4. Immunogenicity - Mean change from baseline in each treatment group in AIA titers after baseline [ Time Frame: Up to Week 26 ]
    The mean change from baseline in each treatment group in AIA titers after baseline and up to visit Week 26.

  5. Immunogenicity - Percentage of subjects with confirmed positive AIA after baseline who develop any anti-insulin neutralizing antibodies after baseline [ Time Frame: Up to Week 26 ]
    The percentage of subjects in each treatment group with confirmed positive AIA after baseline and up to visit Week 26 who develop any anti-insulin neutralizing antibodies after baseline and up to visit Week 26.

  6. Immunogenicity - Percentage of subjects with confirmed positive AIA after baseline [ Time Frame: Up to Week 26 ]
    The percentage of subjects in each treatment group with confirmed positive AIA after baseline and up to visit Week 26.

  7. Safety - The incidence and severity of all treatment-emergent adverse events [ Time Frame: Up to Week 26 ]

    The incidence and severity of all treatment-emergent adverse events and the following subgroups:

    Hypoglycemia, which will be fully documented prospectively in the Hypoglycemic Events Record.

    Serious adverse events, including fatal events. Adverse events leading to termination of the study treatment and/or early withdrawal from the study.

    IP-related adverse events. Injection site reactions. The incidence of clinically significant laboratory abnormalities. The incidence of clinically significant abnormalities in ECG and vital signs.


  8. Efficacy - number and percentage of subjects who achieve an FBG test result of ≤ 8.0 mmol/L (≤ 144.0 mg/dL) at visit Week 26 [ Time Frame: Up to Week 26 ]
    The number and percentage of subjects who achieve an FBG test result of ≤ 8.0 mmol/L (≤ 144.0 mg/dL) at visit Week 26.

  9. Efficacy - The number and percentage of subjects who achieve a HbA1c of < 7.0% [ Time Frame: Up to Week 26 ]
    The number and percentage of subjects who achieve a HbA1c of < 7.0% at visit Week 26.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or nonpregnant, nonlactating female subjects between the ages of 18 and 75 years, inclusive.
  2. Ability to provide written, personally signed, and dated informed consent to participate in the study, in accordance with the ICH GCP Guideline E6 and all applicable regulations, before initiating any study related procedures.
  3. Ability to understand and fully comply with all study procedures and restrictions.
  4. Subjects with a confirmed diagnosis of type 2 diabetes mellitus who meet one of the following:

    1. If insulin-naïve, subjects should have been on at least 2 approved OAMs for at least 12 weeks before screening, and the clinician has decided to add insulin therapy.
    2. If already being treated with a basal and/or bolus insulin, subjects should have been treated with insulin for at least 6 months in addition to at least 1 approved OAM, and must not have changed the type or brand of insulin within 6 months prior to screening.
  5. HbA1c values as follows:

    1. If insulin-naïve, HbA1c ≤ 11.0%.
    2. If previously on a basal insulin regimen, HbA1c ≥ 7.0% and ≤ 11.0%.
  6. Body mass index (BMI) ≤ 45 kg/m2.
  7. Adherence to a prudent diet and exercise regimen recommended by the medical provider, and willingness to maintain these consistently for the duration of the study.
  8. Concomitant medications are allowed, provided that no significant dosing changes are anticipated during the study (see the exclusion criteria below for specific prohibited concomitant medications); for concomitant thyroid medications, subjects must have been on a stable dosage for 90 days before screening.

Exclusion Criteria:

  1. Participation in another clinical study or use of any study drug within 30 days before screening.
  2. Previous use of a biosimilar insulin, either basal or bolus.
  3. Diabetic ketoacidosis within a year before screening.
  4. Brittle type 2 diabetes mellitus within the year before screening (e.g., multiple hospitalizations related to diabetes mellitus and/or severe hypoglycemia for which the subject required 3rd party assistance).
  5. Any severe, delayed sequela of diabetes mellitus, e.g., worsening end-stage renal disease, advanced coronary artery disease, or myocardial infarction within the year before screening, or autonomic peristaltic problems, e.g., gastroparesis.
  6. Anticipated change in insulin used during the study (change in dosage is allowed, but change in type or brand of insulin will result in the subject being withdrawn from the study).
  7. Inadequately controlled thyroid disease, defined as a TSH or free T4 value > the upper limit of normal.
  8. BMI > 45 kg/m2.
  9. Any clinically significant (in the opinion of the Investigator) hematology or chemistry test results at screening, including any liver function test > 3x the upper limit of normal (subjects with elevated bilirubin due to Gilbert syndrome are eligible to participate).
  10. Documented history of anti-insulin antibodies.
  11. Treatment with glucocorticosteroids, immunosuppressants, or cytostatic agents within 60 days before screening (newly-prescribed or high-dose corticosteroids are prohibited; chronically administered oral, inhaled, topical, or intra-articular corticosteroids at a stable dosage are allowed if no increase in dose is anticipated during the study; See Appendix 3 [Section 17.3] for a list of allowed and prohibited concomitant medications).
  12. Current use of medication intended to cause weight loss or weight gain.
  13. Alcohol or substance use disorder within the 2 years before screening.
  14. Any previous or anticipated treatment with interferons.
  15. Any history of malignant disease within 5 years before screening, except for adequately treated basal cell carcinoma.
  16. Severe concomitant physical or psychiatric diseases or conditions.
  17. A history of a positive test result for HIV, hepatitis B, or hepatitis C; any subject who has a positive test result during the study may continue at the discretion of the Investigator.
  18. Any history of pancreatitis or pancreatectomy.
  19. Any diagnosis or condition that requires the subject to undergo procedures that could decrease antibodies in plasma or that would require treatment with immunosuppressant agents.
  20. Any condition e.g., splenectomy, autoimmune disease, or rheumatologic disease, that could affect immunologic responses, could indicate an altered immune system, or could require treatment with a prohibited medication.
  21. Any unresolved infection or a history of active infection within 30 days before screening other than mild or viral illness (as judged by the Investigator).
  22. Any other disease or condition that in the opinion of the Investigator could confound the study results or limit the subject's ability to participate in the study or comply with follow-up procedures; or any other factor that would indicate a significant risk of loss to follow up.
  23. Intolerance or history of hypersensitivity to insulin glargine or any excipient of IP.
  24. Inability or unwillingness to wear the CGM sensor as required for the study, or to comply with the concomitant medication requirements in the FreeStyle Libre Pro Indications and Important Safety Information, during the CGM periods.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03371108


Locations
Show Show 57 study locations
Sponsors and Collaborators
Gan and Lee Pharmaceuticals, USA
Investigators
Layout table for investigator information
Study Director: Jia Lu, PhD Gan & Lee Pharmaceuticals, USA
Principal Investigator: Elena A. Christofides, MD, FACE Endocrinology Research Associates, Inc.
Layout table for additonal information
Responsible Party: Gan and Lee Pharmaceuticals, USA
ClinicalTrials.gov Identifier: NCT03371108    
Other Study ID Numbers: GL-GLAT2-3002
First Posted: December 13, 2017    Key Record Dates
Last Update Posted: January 18, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Gan and Lee Pharmaceuticals, USA:
Diabetes
Diabetes Type 2
Type 2
Basal
Insulin
Glargine
T2DM
Diabetes Mellitus
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin Glargine
Hypoglycemic Agents
Physiological Effects of Drugs